Microparticles of functionalized calcium phosphate salts for passive topical or active topical delivery via a device without the use of needles for biostimulation of collagen production
Functionalized calcium phosphate microparticles for topical delivery via needle-free devices address the limitations of injectable calcium hydroxyapatite, providing safe collagen biostimulation and improved skin hydration in sensitive areas, with targeted delivery to the epidermis and papillary dermis.
Patent Information
- Application Number
- PCT/BR2026/050231
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-15
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current injectable calcium hydroxyapatite formulations for collagen stimulation face challenges such as adverse effects, limited precision in application, and inability to target the papillary dermis, especially in sensitive areas like the periorbital region, and lack effective topical delivery methods.
Functionalized calcium phosphate microparticles with a size of at least 2 micrometers, designed for passive or active topical delivery via needle-free devices, providing anti-aggregant properties, improved interaction with the stratum corneum, and targeted delivery to the epidermis or papillary dermis.
Enables safe, effective collagen biostimulation in thin-skinned areas without needles, reducing adverse effects and enhancing skin hydration and barrier function, while targeting hair follicles for treating skin appendage conditions.
Smart Images

Figure PCTXMLIB-APPB-M000001 
Figure PCTXMLIB-APPB-M000002 
Figure 00000042_0000
Abstract
Description
Functionalized calcium phosphate salt microparticles for passive or active topical delivery via a needle-free device to biostimulate collagen production. Field of Invention
[0001] The present invention belongs to the field of dermatological pharmaceutical technology. It relates to a composition comprising microparticles of calcium phosphate salts functionalized with a component which, after said functionalization process, exhibits advantageous properties not foreseen and not achieved by the physical mixture of excipients, in which at least 20% of the microparticle population has a size of 2 micrometers or more, in which the calcium phosphate salts are employed for the purpose of promoting the biostimulation of collagen production. Among the calcium phosphate salts, hydroxyapatite (Ca 10(PO4)6(OH)2 is the most common form, but it is not limited to this form. Among the functionalizing molecules, starch, sucrose, mannitol, lactose, or others can be used, for example, but are not restricted to these.Its activity may be limited to an anti-aggregant effect, providing superior powder flow performance compared to the physical mixing of excipients. Other active ingredients with complementary effects to the collagen biostimulator effect may also be used, whether cosmetic or pharmacological, such as, but not limited to, hydrating agents like urea, hyaluronic acid, amino acids and peptides; antioxidant agents like melatonin, isoflavones and others; brightening agents like gallic acid; metalloproteinase enzyme inhibitors; enzymatic cofactors relevant to collagen production; polysaccharides; growth factors; or molecules with pharmacological activities related to skin health or skin appendages, such as antibiotics, antifungals, antipruritics, 5-alpha-reductase enzyme inhibitors, among others.The functionalized microparticles of the present invention differ from common hydroxyapatite microparticles in that their surface is modified in such a way that passive topical delivery to the upper portions of the skin and skin appendages becomes feasible when incorporated into appropriate dermatological vehicles. Functionalization therefore provides advantageous properties not foreseen and not achieved by the physical mixing of excipients, such as facilitating their incorporation into dermatological formulations. Furthermore, functionalization ensures ideal ballistic properties for delivery by injection, using a needle-free injection and delivery device.Thus, it becomes possible to promote collagen biostimulation without the use of needles, and this collagen biostimulation effect can be the main effect of the therapy itself or a complementary effect when a molecule is used that simultaneously functionalizes the microparticle and provides another cosmetic or pharmacological effect. Furthermore, the present invention makes it possible, for the first time, to target collagen biostimulation to the epidermis or papillary dermis, since the specific physical characteristics of the functionalized microparticle make targeted delivery to the upper layers of the skin feasible.Furthermore, the present invention makes it possible, for the first time, to apply collagen biostimulation to areas of "thin skin," that is, sensitive areas of the face such as the area around the eyes, where the application of injectable calcium phosphate salt products, mainly hydroxyapatite, is not recommended. In addition, functionalization provides better interaction of the microparticles with the stratum corneum. Functionalization simultaneously prevents aggregation and ensures greater retention in the upper layers for a prolonged time, which can prolong skin hydration and barrier function when appropriate vehicles and functionalizing molecules are used. The functionalized microparticles can be obtained by solvent evaporation and precipitation techniques or any other drying technique such as spray drying, fluidized bed, milling, electrospray, or others, preferably obtained by spray drying.Functionalized microparticles can be administered directly as powders, with or without delivery vehicles, through needle-free delivery devices; simply dispersed in an appropriate aqueous vehicle; or incorporated into liquid formulations, serums, gels, creams, gel-creams or others and delivered after procedures that may or may not damage the skin barrier, such as high and low power lasers, intense pulsed light, physical and chemical peels, iontophoresis, high and low power ultrasound, micro and macro-focused ultrasound, microneedling or others. State of the Art
[0002] Aging is influenced by intrinsic factors, related to the natural loss of cellular functions over time, and by extrinsic factors, especially exposure to ultraviolet (UV) radiation. Exposure to UV radiation increases levels of matrix metalloproteinases (MMPs), enzymes responsible for the degradation of collagen fibers and other components of the extracellular matrix of the dermis. Therefore, cutaneous photoaging exhibits distinct characteristics, including loss of elasticity, age spots, thinning of the epidermis, telangiectasias, and wrinkles. In this context, it is estimated that the skin undergoes a decrease of approximately 1% per year in collagen fibers during the aging process (GANCEVICIENE et al. Dermato-Endocrinol., 4(3): 308-319, 2012; QUAN et al., J. Invest. Dermatol., 133(5):1362-1366, 2013).
[0003] Regarding the intrinsic factors of skin aging, there is a significant decrease in the production of type I collagen, compromising the skin's resistance and elasticity, since there is a natural dysfunction of fibroblasts, which play a crucial role in collagen synthesis, essential for the structural integrity of the skin. Furthermore, fibroblast dysfunction can be aggravated by photoaging, also resulting in elevated levels of MMPs, contributing to tissue laxity and alterations in skin structure. In this sense, the balance in collagen homeostasis plays a crucial role in maintaining skin health, and its dysfunction is one of the hallmark characteristics of aging (QUAN et al., J. Invest. Dermatol., 133(5):1362-1366, 2013).
[0004] Type VII collagen present at the dermo-epidermal junction decreases with aging, leading to a weakening of this bond and promoting the appearance of more pronounced wrinkles. It is known that there is a reduction in the proportion of lipids and water in aged skin, compromising the natural moisturizing factor, in addition to an increase in the pH of the stratum corneum and consequent weakening of the barrier function, increasing susceptibility to infection and induced mechanical stress, resulting in rougher skin texture and the appearance of fine wrinkles. (ZARGARAN et al., Int. J. Cosmet. Sci., 44(4): 414-420, 2022).
[0005] The demand for injectable aesthetic procedures is growing worldwide, aiming to improve the signs of aging. The American Society of Plastic Surgery (ASPS) demonstrated a 174% increase in demand for minimally invasive aesthetic procedures in the last decade, such as botulinum toxin, fillers, lasers, and collagen biostimulators. However, despite the benefits of these types of procedures, there is a possibility of adverse effects such as infections, vascular occlusion, and hypersensitivity reactions, as well as nodules and granulomas (KADOUCH, J. Cosmet. Dermatol., 16(2): 152-161, 2017). Although the incidence of complications is low and most adverse events are mild, the increase in the number of procedures has produced a concomitant increase in the number of complications. Serious complications are rare, although probably underreported (URDIALES-GÁLVEZ et al., Aesthetic Plast. Surg., 42(2): 498-510, 2018).
[0006] Calcium phosphate salts comprise the major mineral constituent of bones and teeth. Among phosphate salts, Calcium Hydroxyapatite (CaHA) represents the most stable crystalline form of the phosphate mineral group (FIUME et al., Ceramics, 4(4): 542-563, 2021). This apatite is widely used in clinical applications for bone and dental regeneration due to its excellent biocompatibility, lack of toxicity, and similarity to the chemical composition of the mineral phase of calcified tissues (KUMTA et al., Acta Biomater., 1(1): 65-83, 2005).
[0007] This compound is used in the treatment of aging aspects in non-surgical rejuvenation procedures, via injection, forming part of the composition of products with volumizing and filling properties, resulting from the carboxymethylcellulose gel in which CaHA microspheres are embedded, as a primary action. After injection of the material, the carboxymethylcellulose gel is degraded and the CaHA particles act by stimulating neocollagenesis. Currently, this material is diluted in physiological saline so that there is dispersion of the CaHA microspheres, and it only presents the function of stimulating collagen production (DE ALMEIDA et al., Aesthetic Plast. Surg., 7(3): 1-9, 2019).
[0008] Following the injection of CaHA into the dermis, an initial inflammatory process occurs, triggering a foreign body reaction. Macrophages, originating from monocytes, migrate to the site through various processes. Fibroblasts surrounding the CaHA particles stimulate the production of growth factors, promoting the formation of granulation tissue. This tissue includes new blood vessels, fibroblasts, inflammatory cells, and other temporary components. As CaHA degrades, type III collagen is replaced by type I collagen. It is important to note that calcification and osteogenesis are not possible after the application of CaHA to the dermis. This limitation stems from the absence of osteogenesis progenitor cells in soft tissues (KIM, Clin. Cosmet. Investig. Dermatol., 12: 771-784, 2019; VAN LOGHEM; YUTSKOVSKAYA; WERSCHLER, J. Cosmet. Dermatol., 17(6): 1025-1030, 2015).
[0009] Although CaHA is a biocompatible material with the human body, its injectable use for aesthetic purposes such as rejuvenation, filling, and collagen stimulation can lead to some adverse events and complications (KADOUCH, J. Cosmet. Dermatol., 16(2): 152-161, 2017). The adverse effects or actual complications can be categorized into immediate complications, occurring up to two weeks after application, such as vascular compromise, asymmetries, superficial applications, and nodule formation. In addition, there are late complications, manifesting after two weeks of application, such as the appearance of granulomas, infections associated with biofilms, and migration of the material.
[0010] Specifically, vascular compromise can occur when the product is improperly injected into an artery, or often due to the large volume of product used, causing vascular compression. This compression impedes local blood circulation and compromises tissue oxygenation, leading to ischemia with subsequent necrosis. If left unresolved, the ischemia progresses to the formation of reticular yeast in the skin, accompanied by slow capillary return. Depending on the extent of the lesion, it can lead to necrosis of overlying tissue (KADOUCH, J. Cosmet. Dermatol., 16(2): 152-161, 2017; SHI et al., Aesthet. Surg. J., 36(6): 712-717, 2016). Nodules can be caused by superficial applications of the material and errors in the application technique, being classified as recent nodules. Late nodules arise from the accumulation and / or aggregation of particles due to displacement.The application of sterile water injections and interlesional corticosteroids may be an option for treating these nodules (KADOUCH, J. Cosmet. Dermatol., 16(2): 152-161, 2017). In order to reduce the risks and adverse effects of injectable calcium hydroxyapatite application, the topical use of calcium hydroxyapatite becomes an alternative. However, it is known that, even after using devices to improve transcutaneous administration such as lasers, microneedling, fractional radiofrequency microneedling, the topical application of calcium hydroxyapatite present in commercial formulations developed so far is not effective (CERVANTES et al., Dermatol. Surg., 49(9): 865-870, 2023; UGWU et al., Dermatol. Surg., 50(9): 829-833, 2024).The permeation and passive penetration of active ingredients depends on the characteristics of the active ingredient, being restricted to a few molecules, which must be able to achieve the therapeutic effect at low concentrations, have a low molecular weight (<500 Da) and adequate solubility in hydrophilic and hydrophobic media, being lipophilic to cross the stratum corneum but possessing sufficient hydrophilicity to penetrate the viable epidermis. However, the amount that penetrates the skin almost always depends on the pharmaceutical form used (OH et al., Ther. Innov. Regul. Sci., 55: 1059-1065, 2019; BRAIN et al., Toxicol. In Vitro, 21(1): 133-138, 2007; BARRY, Eur. J. Pharm. Sci., 14(2):101-114, 2001).
[0011] The present invention presents itself as a novel and advantageous alternative, based on the particle characteristics obtained through a functionalization process, for passive or active topical use by a needle-free calcium hydroxyapatite device, being used for collagen biostimulation with preferential targeting to the papillary dermis.
[0012] It is known that the human dermis has two layers: the papillary dermis, which is more superficial and directly connected to the epidermis, rich in type III collagen and hyaluronic acid; and the reticular dermis, which is deeper and contains mainly type I collagen and thick elastic fibers (ARDA et al., Clin. Dermatol., 31(1): 3-13, 2014). Intradermal applications of calcium hydroxyapatite could promote greater collagen stimulation compared to subdermal applications. However, these are impossible to perform with the formulations described so far, because, without functionalization, superficial injectable applications can lead to nodule formation (COLEMAN et al., Dermatol. Surg. 34: S53-S55, 2008). Therefore, even when subcutaneous injections are performed with small-gauge needles, the entire formulation is applied to the reticular dermis and often to the subcutaneous tissue immediately below. Injections cannot reach the papillary dermis.Furthermore, keloids and hypertrophic scars can be generated due to continuous inflammation in the reticular dermis, thus making injectable administration of collagen biostimulators contraindicated in patients with a greater genetic predisposition to their formation, such as people with dark skin, who have a fifteen times higher risk of forming unsightly scars when compared to people with light skin (OGAWA, Int. J. Mol. Sci., 18(3): 606, 2017). The novel targeting of the papillary dermis in the present invention presents an advantage, since superficial injuries that do not reach the reticular dermis do not cause the formation of keloids and hypertrophic scars. Furthermore, it is known that hyaluronic acid present in the papillary dermis cross-links with extracellular matrix proteins, such as collagen, resulting in increased skin firmness and performing space-filling functions (SHIN et al., Int. J. Mol. Sci., 20(9): 2126, 2019), which is yet another advantage of the present invention.
[0013] Topical treatment of fine lines currently focuses, in most cases, on increasing skin hydration, especially in areas with thin skin, such as the periorbital region. Available cosmetics work by delaying transepidermal water loss and temporarily hydrating the skin until the product is removed by cleansing. Although wrinkle reduction may seem like a functional benefit, it results from a temporary increase in skin hydration, unless the skin barrier is repaired (DRAELOS, J. Cosmet. Dermatol., 17(2): 138-144, 2018). The present invention surpasses current commercial formulations by using functionalized calcium hydroxyapatite microparticles, including moisturizing actives present in the extracellular matrix and responsible for the natural moisturizing factor, such as urea, but not limited to it.Thus, hydroxyapatite microparticles functionalized with urea can, for example, provide the functional benefit of collagen biostimulation and, in addition, prolong skin hydration for a longer time than would happen with the physical mixture of these two excipients; that is, the hydration provided by the microparticle functionalized with urea persists for a longer time than the hydration provided by the use of the microparticle mixed with urea, without going through the functionalization process.
[0014] The periorbital region is one of the first areas to show signs of skin aging. It has an extremely thin dermis, averaging 0.6 mm in thickness (ARDA et al., Clin. Dermatol., 31(1): 3-13, 2014). Due to its delicate anatomy, it requires safe and effective aesthetic interventions. The use of existing injectable calcium hydroxyapatite formulations in this region is strongly discouraged due to the lack of precision in application and increased risk of complications, such as vascular compression, being used only off-label by experienced injecting professionals, since the region, in addition to having a delicate dermis, is highly vascularized, making it necessary to avoid branches of the maxillary artery, angular artery, superior labial artery and septal artery at the time of application (EVANS et al., Arch. Dermatol. Res., 313(9): 711-727, 2021; DIAS, BORBA, Res. Soc. Dev., 2021).The present invention presents itself as an effective and safe alternative for the treatment of this area, since its characteristics allow its use in a passive or active topical manner without the use of needles.
[0015] It is known that, in addition to the stratum corneum, the follicular route becomes an alternative route for the penetration of topical medications and cosmetic actives. The use of nano and microparticles with the ability to target the hair follicle has been widely used, mainly for the treatment of conditions affecting skin appendages, such as alopecia. The present technology is advantageous for the treatment of such conditions, since it has the ability to target the hair follicle due to its size and targeting of the papillary dermis, and can also act as a delivery system for actives intended for the treatment of such conditions, such as dutasteride, but is not limited to it, reducing adverse effects such as loss of libido and sexual impotence reported by patients undergoing oral treatment, due to its topical use.It is known that collagen XVII is essential for the regulation of hair follicle stem cells, their self-renewal and differentiation capacity. It is known that fibroblast proliferation and increased Ki-67 expression aid in the treatment of alopecia, and that oral use of hydrolyzed collagen promotes papillary dermis cell proliferation and hair growth (SHIRAI et al., Tissue and Cell, 59: 33-38, 2019; HWANG, PARK, LEE, Mar. Drugs, 21(9): 475, 2023; KIM et al., J. Microbiol. Biotechnol., 34(1): 17-28, 2024; CORREIA et al., Biomater., 302: 1-42, 2023). Therefore, the present technology becomes advantageous for this purpose, since it acts as a delivery system for active substances for the treatment of skin appendages, such as dutasteride, but is not limited to it, being directed to the hair follicle due to its size and density, in addition to acting on the biostimulation of collagen in the region.
[0016] In this context, the present invention surpasses current commercial formulations by being functionalized microparticles that allow for application via a route other than injection. Functionalization has multiple functions: (1) acting as an anti-aggregant, improving its dispersion and incorporation into topical dermatological formulations such as serums, gels, gel-creams, creams, suspensions, among others; (2) ensuring greater stability of dermatological formulations due to less aggregation of microparticles during storage; (3) improving interaction with the stratum corneum by being less aggregated and by reducing the total volume of pores and the surface area of the particle, enabling passive topical delivery after procedures that may or may not damage the stratum corneum;(4) to provide better interaction and longer-lasting and extended retention in the upper layers of the skin, which can promote skin hydration and barrier retention, crucial for the desirable cosmetic appearance of hydrated skin; (5) to facilitate its targeting to the hair follicle, another route of topical permeation, which may bring advantages in the treatment of aesthetic dysfunctions that affect skin appendages, such as androgenetic alopecia, traction alopecia, telogen effluvium, among others; (6) to make these particles have ideal ballistic properties by providing lower porosity and lower surface roughness, enabling active permeation with the use of needle-free devices that use pressure, with the advantage of directing the formulation to the upper strata of the skin, where there is a greater number of cells involved in the biological process of collagen formation and a more visible cosmetic result of fine lines.
[0017] All these advantages observed after the functionalization process are innovative, unforeseen properties that are not obtained with the simple physical mixing of calcium salt particles and functionalizing agents.
[0018] Several techniques can be used to functionalize calcium salt microparticles, including conventional spray drying, fluidized bed drying, or nanospray drying.
[0019] Patent document CN 1736365 describes the process for preparing galactose hydroxyapatite-polysine nanoparticles, which includes (1) obtaining an aqueous solution of poly-D-lysine, alpha-lactose and sodium cyanogen borate; (2) pre-treatment and purification of the hydroxyapatite nanoparticles; and (3) treatment of the nanoparticles with the poly-D-lysine solution, obtaining the product. The described particles are used in gene therapy for primary liver cancer, extending to gene therapy for viral herpes. The present invention differs entirely from this one by involving different products with a completely different purpose of use, not presenting a technical solution for topical application of calcium hydroxyapatite for collagen biostimulation, nor for the treatment of aesthetic dysfunctions affecting the cutaneous appendages. The nanoparticles described do not possess the unforeseen characteristics that the functionalized microparticles described here possess.
[0020] International publication WO 2022 164776 describes an injectable composition comprising calcium hydroxyapatite particles obtained by heat treatment, employed in a cosmetic method for wrinkle prevention and skin rejuvenation. However, the present invention differs completely due to the functionalization of the microparticles, which allows for topical use or application via needle-free devices, thus overcoming all the disadvantages of injectable application.
[0021] Other patent documents that cite the use of hydroxyapatite particles for cosmetic treatments include the applications described below. Publication WO 2017 009206 describes a formulation containing an oil phase, surfactant, and calcium hydroxyapatite nanoparticles, which are used as topical drug / cosmetic carriers. However, the formulation only includes calcium hydroxyapatite nanoparticles that are not functionalized with an anti-aggregant agent and, therefore, these particles do not have properties that prevent aggregation and actually enable skin penetration, as is the case with the present invention. The document also does not mention how to obtain such particles or their preferred size range.
[0022] Patent document JP 2017 014118 concerns an injectable hydrogel containing calcined hydroxyapatite particles for cosmetic applications. Patent BR 11 2019 0014926 refers to the manufacture of composite material filaments comprising hyaluronic acid and hydroxyapatite for use in cosmetic applications. Publication WO 2008 098007 describes tissue fillers used in aesthetic procedures, which mention calcium hydroxyapatite particles and other components in their composition. However, the present invention differs completely from all these inventions by functionalizing the microparticles, enabling their topical use or application with needle-free devices. This overcomes all the disadvantages of injectable application and provides all the advantages described for functionalization.
[0023] US patent document 8,445,002 discloses micrometric spherical compositions of calcium hydroxyapatite for dermal delivery of active ingredients for various purposes. However, the present invention differs in several aspects, both technical and in terms of use and application. Technically, the present invention relates to completely different particles. While invention US 8,445,002 refers to microparticles in which at least 90% of the particles have a diameter of 2 micrometers or less, the present invention deals with much larger particles, in which at least 20% of the particles have a diameter of 2 micrometers or more. This difference in size range is not a mere technicality or coincidence.The size range and functionality of the present invention are key features of the inventiveness defended herein, as these features provide unique cosmetic and / or therapeutic benefits, such as (1) improved targeting to hair follicles, which can bring exceptional advantages in the treatment of conditions affecting skin appendages; (2) providing better interaction and longer-lasting and extended retention in the stratum corneum, which can promote skin hydration and barrier retention, crucial for the desirable cosmetic appearance of hydrated skin; and (3) being denser, providing ideal conditions for ballistic delivery through the use of needle-free devices.These first two advantages are counterintuitive, since a person skilled in the art might think that the larger the particle, the worse the targeting to the follicle would be, especially considering the micro size, and also that the larger the size, the worse the interaction with the stratum corneum would be. However, the functionalization process surprisingly demonstrated that the particles obtained have superior targeting and interaction than would be expected for this type of material. It should be noted that the use of needle-free delivery devices is not foreseen in invention US 8,445,002, but even if it were, the minute size of the particles would make them unfeasible.In fact, in this aspect the present invention brings another unprecedented and unexpected result, since the patents related to this type of device, such as US 6881200 B2, describe particles of 10 to 40 micrometers as ideal characteristics for ballistic delivery; however, the functionalization described here reduces the surface roughness and pore volume so that even with particles averaging 6 micrometers, they meet the ideal characteristics for ballistic delivery, which would not be possible with the physical mixing of the excipients, which does not alter these characteristics. Thus, the crucial advantage of targeted collagen biostimulation in the upper layers of the skin with needle-free application is only feasible using the formulation described in the present invention. It should also be noted that in invention US 8.445,002 cited, such particles are used merely as drug carriers, and not as a collagen-stimulating product, therefore the use of hydroxyapatite for collagen biostimulation is also not understood.
[0024] Patent application BR 10 2024 007162 0 presents calcium hydroxyapatite nanoparticles functionalized with an anti-caking agent and obtained by a drying method. However, the hydrodynamic size range presented is 100 to 900 nm, lower than that presented in the present invention, which also brings the same limitations cited in the previous example.
[0025] Active topical delivery of calcium hydroxyapatite using needle-free devices in the superficial layers of the skin is effective (WEISSMUELLER et al., Clin. Vaccine Immunol., 22(5): 586-592, 2015). Weissmueller et al (2015) demonstrate that the thickness of the stratum corneum in different regions of the human body can impact the penetration of calcium hydroxyapatite microparticles into the skin, but that the characteristics of the particle, the injection device, and the propulsion pressure are more relevant to the effectiveness of the treatment due to the impact on the distribution of the powder in the dermis.Although it features the active topical use of calcium hydroxyapatite, including in conjunction with potassium, the microparticle presented in this study differs from the present invention because it does not aim to biostimulate collagen and treat skin and skin appendage conditions, and the microparticles used do not possess the advantages provided by functionalization, such as prolonged hydration or, for example, viability for the treatment of alopecia, among other things. Furthermore, the present invention presents optimized microparticles specifically designed to target thin skin areas such as the eye area, which ensures the superior use of this technology.
[0026] It is known that calcium hydroxyapatite is widely used for drug delivery with applications in the biomedical field because it provides controlled delivery of drugs to achieve a constant concentration in the body for a determined time, without undesirable side effects. The chemical properties and structural characteristics of the substrates and drug molecules play an important role in drug adsorption and release (MASHAK, BAZRAEE, MOBEDI, Bull. Mater. Sci., 45(183): 1-17, 2022).
[0027] Several studies present micro and nanometric-sized calcium hydroxyapatite for drug delivery of various drugs to treat diverse conditions, such as cancer, bacterial infections, controlled protein delivery, among others. Li et al (2021) used calcium hydroxyapatite microparticles with strontium and simvastatin to promote angiogenesis and osteogenesis. Wang et al (2017) used calcium hydroxyapatite microparticles without other compounds for controlled delivery of simvastatin.
[0028] Huang et al (2020) and Liu et al (2021) used calcium hydroxyapatite microparticles for sustained and controlled administration of doxorubicin. Prakash et al (2019) and Prasad, Jayakrishnan, and Kumar (2019) used calcium hydroxyapatite nanoparticles with PVA films for the delivery of amoxicillin for the treatment of periodontitis and methotrexate and gemcitabine for the treatment of cancer, respectively. Parente et al (2016) used microporous calcium hydroxyapatite as a reservoir for vancomycin. Zang et al (2014) used calcium hydroxyapatite as a vehicle for controlled protein delivery. Ito, Kamitakahara, and Ioku (2014) developed porous calcium hydroxyapatite particles to incorporate methotrexate for the treatment of osteosarcoma.
[0029] Despite the extensive use of calcium hydroxyapatite microparticles and nanoparticles for drug delivery and other purposes, none of the cited documents anticipates a composition comprising calcium phosphate salt microparticles functionalized with a component that, after said functionalization process, exhibits advantageous properties not foreseen and not achieved by the physical mixture of excipients, in which at least 20% of the microparticle population is 2 micrometers or larger, in which the calcium phosphate salts are employed for the purpose of promoting the biostimulation of collagen production and the functionalizing agent has an anti-aggregant action or is complementary to collagen biostimulation, wherein the functionalization provides: (1) anti-aggregant property, improving dispersion in aqueous phase and dispersion in topical dermatological formulations such as serums, gels, gel-creams, creams, suspensions,among others; (2) greater stability of dermatological formulations with less aggregation of microparticles during storage; (3) better interaction with the stratum corneum, through two mechanisms, firstly by being less aggregated, secondly by the functionalization providing a less rough particle surface (smaller surface area) improving the interaction of the particle with the skin, enabling passive topical delivery after procedures that may or may not damage the stratum corneum; (4) prolonged interaction time with the upper layers of the skin, which may provide desirable complementary cosmetic or pharmacological effects, such as prolonged hydration; (5) greater targeting to hair follicles, which may provide desirable complementary cosmetic or pharmacological effects, such as targeting molecules that should preferentially act on hair follicles; (6) reduced particle porosity,providing ideal ballistic properties that enable its use in needle-free pressure injection devices for liquids or solids, the use of needle-free administration devices has the unique advantage for the intended use of collagen biostimulation, which is to direct the formulation to the upper layers of the skin, where there is a greater quantity of cells involved in the biological process of collagen formation and a more visible cosmetic result in fine lines. All these advantages are not observed in the cited articles, and are only observed after the process that leads to functionalization; they are innovative, unforeseen properties that are not obtained with the simple physical mixing of calcium salt particles and functionalizing agents. Some of these properties are, in fact, counterintuitive, since a person skilled in the art might think that because the particles mentioned are larger than 2 micrometers,They are too large to interact with the stratum corneum and penetrate the skin, and experiments prove that such unexpected properties were obtained through functionalization.
[0030] Furthermore, the present invention makes it possible for the first time to target collagen biostimulation to the epidermis or papillary dermis, since the specific physical characteristics of the functionalized microparticle make targeted delivery to the upper layers of the skin feasible. In addition, the present invention makes it possible for the first time to apply collagen biostimulation to areas of "thin skin," i.e., sensitive areas of the face such as the area around the eyes, where the application of injectable hydroxyapatite products is not recommended. Summary of the invention
[0031] The objective of the present invention is to present a composition comprising calcium phosphate salt microparticles functionalized with a component that, after said functionalization process, provides advantageous properties not foreseen and not achieved by the physical mixture of excipients, in which at least 20% of the microparticle population has a size of 2 micrometers or more, in which the calcium phosphate salts are employed for the purpose of promoting the biostimulation of collagen production. The functionalizing molecules may have their activity restricted to an anti-aggregant effect or, in addition to the anti-aggregant effect, present a cosmetic or pharmacological effect complementary to the collagen biostimulating effect. The functionalization presented here guarantees innovative technical advantages, namely: 1) Reduced aggregation of microparticles, facilitating incorporation into dermatological formulations such as serums, gels, creams, and others;2) Greater stability of dermatological formulations with less aggregation of microparticles during storage; 3) Better interaction with the stratum corneum, through two mechanisms: first, due to less aggregation, and second, due to the functionalization providing a less rough surface; 4) Prolonged interaction time with the upper layers of the skin, which can provide desirable complementary cosmetic or pharmacological effects, such as prolonged hydration; 5) Greater targeting of hair follicles, which can provide desirable complementary cosmetic or pharmacological effects, such as targeting molecules that should preferentially act on hair follicles;6) Lower particle porosity and reduced surface roughness decrease aggregation while simultaneously making it denser, resulting in microparticles with ideal ballistic characteristics for delivery via needle-free pressure delivery devices. This provides an innovative use of the material for targeted collagen biostimulation in the upper layers of the skin, such as the epidermis and papillary dermis, enabling aesthetic treatments in sensitive and thin-skinned areas such as around the eyes and lips. It should be understood that the present invention is not limited to the particular embodiments described herein, as these may vary. The nomenclature used herein for the present invention is only for the purpose of describing particular embodiments and is not limiting. Brief description of the figures
[0032] The invention can be better understood based on Figures 1 to 41, whose descriptions follow below:
[0033] [Fig. 1] shows a scanning electron microscopy (SEM) photomicrograph of lactose-functionalized particles obtained by spray drying (CaHA Lac Spray).
[0034] [Fig. 2] presents a graphical representation of the size distribution of lactose-functionalized particles obtained by spray drying (CaHA Lac Spray).
[0035] [Fig. 3] presents a graphical representation of the size distribution of urea-functionalized particles obtained by spray drying (CaHA Urea).
[0036] [Fig. 4] presents the graphical representation of the particle size distribution of caffeine-functionalized particles obtained by spray drying (CaHA Caffeine).
[0037] [Fig. 5] presents a graphical representation of the average particle size of the physical mixture of lactose with microparticles obtained by a drying process without functionalization (CaHA Lac Physical Mixture), functionalized CaHA microparticles (CaHA Lac Spray), and CaHA microparticles (CaHA Spray) incorporated into serum over time.
[0038] [Fig. 6] shows the visual characteristics of the CaHASpray microparticle during each incorporation time in the metabisulfite base serum and lecigel, as well as illustrating its spreadability at each of these times.
[0039] [Fig. 7] shows the visual characteristics of the CaHA Lac microparticle during each incorporation time in the metabisulfite base serum and lecigel, as well as illustrating its spreadability at each of these times.
[0040] [Fig. 8] presents the visual characteristics of the CaHA Lac microparticle physical mixture during each incorporation time in the metabisulfite base serum and lecigel, in addition to illustrating its spreadability at each of these times.
[0041] [Fig. 9] presents a graphical representation of the spreadability of CaHA-based microparticles (CaHA Spray, CaHA Lac, CaHA Lac physical mixture) at each incorporation time in the metabisulfite-based serum and lecigel.
[0042] [Fig. 10] presents the graphical representation of the true density measured by gas pycnometry of calcium hydroxyapatite (CaHA), lactose, physical mixture CaHA Lac, functionalized CaHA Lac microparticles.
[0043] [Fig. 11] presents the graphical representation of the true density measured by gas pycnometry of calcium hydroxyapatite (CaHA), urea, physical mixture CaHA urea, microparticles of functionalized CaHA urea.
[0044] [Fig. 12] presents the graphical representation of the true density measured by gas pycnometry of calcium hydroxyapatite (CaHA), caffeine, physical mixture CaHA caffeine, microparticles of functionalized CaHA caffeine.
[0045] [Fig. 13] presents the graphical representation of the aerated density measured by the PT-N Hosokawa equipment of calcium hydroxyapatite (CaHA), CaHA microparticles functionalized with lactose (CaHA Lac), urea (CaHA Urea), and caffeine (CaHA Caffeine).
[0046] [Fig. 14] presents the graphical representation of the compacted density measured by the Hosokawa PT-N equipment of calcium hydroxyapatite (CaHA), CaHA microparticles functionalized with lactose (CaHA Lac), urea (CaHA Urea), and caffeine (CaHA Caffeine).
[0047] [Fig. 15] presents a graphical representation of the compressibility of calcium hydroxyapatite (CaHA), CaHA microparticles functionalized with lactose (CaHA Lac), urea (CaHA Urea), and caffeine (CaHA Caffeine).
[0048] [Fig. 16] shows the differential scanning calorimetry (DSC) of calcium hydroxyapatite (CaHA), lactose, a physical mixture of lactose with microparticles obtained by a drying process without functionalization (CaHA Lac Physical Mixture), CaHA microparticles functionalized with lactose (CaHA Lac Spray), and CaHA microparticles (CaHA Spray).
[0049] [Fig. 17] shows the differential scanning calorimetry (DSC) of calcium hydroxyapatite (CaHA), urea, a physical mixture of urea with microparticles obtained by a drying process without functionalization (CaHA Urea Physical Mixture), and CaHA microparticles functionalized with urea (CaHA Urea).
[0050] [Fig. 18] shows the differential scanning calorimetry (DSC) of calcium hydroxyapatite (CaHA), caffeine, a physical mixture of caffeine with microparticles obtained by a drying process without functionalization (CaHA Caffeine Physical Mixture), and CaHA microparticles functionalized with caffeine (CaHA Caffeine).
[0051] [Fig. 19] presents the thermogravimetric analysis (TGA) of calcium hydroxyapatite (CaHA), lactose, a physical mixture of lactose with microparticles obtained by a drying process without functionalization (CaHA Lac Physical Mixture), functionalized CaHA microparticles (CaHA Lac Spray), and CaHA microparticles (CaHA Spray).
[0052] [Fig. 20] presents the thermogravimetric analysis (TGA) of calcium hydroxyapatite (CaHA), urea, a physical mixture of urea with microparticles obtained by a drying process without functionalization (CaHA Urea Physical Mixture), and CaHA microparticles functionalized with urea (CaHA Urea).
[0053] [Fig. 21] presents the thermogravimetric analysis (TGA) of calcium hydroxyapatite (CaHA), caffeine, a physical mixture of caffeine with microparticles obtained by a drying process without functionalization (CaHA Caffeine Physical Mixture), and CaHA microparticles functionalized with caffeine (CaHA Caffeine).
[0054] [Fig. 22] shows the Fourier Transform Infrared Spectroscopy (FTIR) of lactose, a physical mixture of lactose with microparticles obtained by a drying process without functionalization (CaHA Lac Physical Mixture), functionalized CaHA microparticles (CaHA Lac Spray), and CaHA microparticles (CaHA Spray).
[0055] [Fig. 23] shows the Fourier Transform Infrared Spectroscopy (FTIR) of urea, a physical mixture of urea with microparticles obtained by a drying process without functionalization (CaHA Urea Physical Mixture), functionalized CaHA microparticles (CaHA Urea), and CaHA microparticles (CaHA Spray).
[0056] [Fig. 24] shows the Fourier Transform Infrared Spectroscopy (FTIR) of caffeine, a physical mixture of caffeine with microparticles obtained by a drying process without functionalization (CaHA Caffeine Physical Mixture), functionalized CaHA microparticles (CaHA Caffeine), and CaHA microparticles (CaHA Spray).
[0057] [Fig. 25] shows the X-ray Diffraction (XRPD) spectra of calcium hydroxyapatite (CaHA), lactose, a physical mixture of CaHA with lactose without functionalization (CaHA Lac Physical Mixture), and CaHA microparticles functionalized with lactose (CaHA Lac).
[0058] [Fig. 26] shows the X-ray powder diffraction (XRPD) spectra of calcium hydroxyapatite (CaHA), urea, a physical mixture of CaHA with urea without functionalization (CaHA urea Physical Mixture), and CaHA microparticles functionalized with urea (CaHA urea).
[0059] [Fig. 27] shows the X-ray Diffraction (XRPD) spectra of calcium hydroxyapatite (CaHA), caffeine, a physical mixture of CaHA with caffeine without functionalization (CaHA Caffeine Physical Mixture), and CaHA microparticles functionalized with caffeine (CaHA Caffeine).
[0060] [Fig. 28] shows the pore diameter of calcium hydroxyapatite (CaHA), functionalized CaHA microparticles (CaHA Lac Spray), and CaHA microparticles (CaHA Spray).
[0061] [Fig. 29] shows the surface area of calcium hydroxyapatite (CaHA), functionalized CaHA microparticles (CaHA Lac Spray), and CaHA microparticles (CaHA Spray).
[0062] [Fig. 30] shows the swelling capacity of the physical mixture of lactose with microparticles obtained by a drying process without functionalization (CaHA Lac Physical Mixture), functionalized CaHA microparticles (CaHA Lac Spray), and CaHA microparticles (CaHA Spray) for up to 1440 min.
[0063] [Fig. 31] shows the swelling capacity of the physical mixture of urea with microparticles obtained by a drying process without functionalization (CaHA Urea Physical Mixture), functionalized CaHA microparticles (CaHA Urea), and CaHA microparticles (CaHA Spray) for up to 1440 min.
[0064] [Fig. 32] shows the amount of commercial hydroxyapatite (Radiesse®), CaHA microparticles with added lactose (CaHA Lac Physical Mixture) and functionalized CaHA microparticles (CaHA Lac Spray) incorporated into serum at a concentration of 50 mg / g passively permeated into the skin layers of pig ears for a period of 24 hours.
[0065] [Fig. 33] shows the amount of free Dutasteride (Duta) and functionalized CaHA microparticles (CaHA Duta Spray) incorporated into serum at a concentration of 0.25 mg / mL passively permeated into the skin layers of pig ears for a period of 12 hours.
[0066] [Fig. 34] presents the targeting factor of Dutasteride to the hair follicle given by the following formula: FD = HF / (SC + HF + PR), where FD is the targeting factor, HF is the amount of drug quantified in the hair follicle; SC is the amount of drug quantified in the stratum corneum and PR is the amount of drug quantified in the remaining skin. The graph represents the FD from formulations containing free Dutasteride (Duta) and from functionalized CaHA microparticles (CaHA Duta Spray) incorporated into serum at a concentration of 0.25 mg / mL, passively permeated into the skin layers of pig ears for a period of 12 hours.
[0067] [Fig. 35] presents an evaluation of the cytotoxicity of micro CaHA in (A) corresponding to fibroblasts, (B) corresponding to PBMCs, and (C) corresponding to HaCat exposed to different concentrations for 48 hours. The data were subjected to normality analysis and subsequently evaluated by Two-way ANOVA, followed by Tukey's post-hoc test for multiple comparisons between concentrations.
[0068] [Fig. 36] presents an evaluation of the cumulative cytotoxicity in fibroblasts initially seeded at different cell densities, treated with 0.0625% of each formulation tested for periods of 7, 14, 21, and 28 days. The data were subjected to normality analysis and subsequently evaluated by ANOVA, followed by Tukey's post-hoc test for multiple comparisons between groups.
[0069] [Fig. 37] shows an evaluation of cell viability after 48 (A) hours and 7 days (B) of topical treatment with Serum containing Standard CaHA, Functionalized CaHA and CaHA Spray.
[0070] [Fig. 38] shows an evaluation of collagen deposition after (A) 48 hours and (B) 7 days of treatment with 0.0625% of each treatment. Cells were fixed in 20% formalin and stained with alizarin red to assess calcium deposits.
[0071] [Fig. 39] shows intra- and extracellular collagen production in fibroblasts treated only with micro CaHA (A), in fibroblasts treated with micro CaHA plus the supernatant of PBMCs previously treated for 48 hours (B), and finally, fibroblasts maintained in co-culture with PMBCs (C).
[0072] [Fig. 40] shows quantification of intra- and extracellular collagen after 48 hours of treatment with different formulations. For the experiment, 70,000 fibroblasts were exposed to 0.0625% of each formulation, being cultured in the presence of HaCat supernatants previously treated for 48 hours with the same concentration (0.0625%) of the respective formulations.
[0073] [Fig. 41] presents an evaluation of collagen fibers after 48 hours (A), 7 days (B), and 14 days (C) of treatment, showing the unmarked, control, physical mixture, and functionalized CaHa samples. Detailed description of the invention
[0074] In general, the present invention comprises functionalized microparticles of calcium phosphate salts, preferably calcium hydroxyapatite.
[0075] The functionalized calcium hydroxyapatite microparticles of the present invention have a spherical shape with a slightly rough surface (Figure 1). They have a hydrodynamic size between 1 and 20 μm, in which at least 20% of the microparticle population has a size of 2 micrometers or more, a polydispersity index between 0.1 and 0.8, and a zeta potential between -30.0 and +30.0 mV, depending on the functionalizing agent chosen. This effect may be limited to an anti-aggregant effect or, in addition to the anti-aggregant effect, may have a complementary effect to the collagen biostimulation effect, whether cosmetic or pharmacological. The characteristics of the obtained microparticles, such as their size, spherical morphology, reduced pore diameter, and smaller particle surface area, improve their interaction with the stratum corneum in a passive or active topical application without the use of a needle.
[0076] Optionally, the functionalized Micro CaHA has a particle size of 6.352 ± 3.201 μm.
[0077] Optionally, the functionalized Micro CaHA exhibits a polydispersity index of 0.412 ± 0.030.
[0078] Optionally, functionalized Micro CaHA exhibits a zeta potential of -14.6 mV.
[0079] Functionalized microparticles can be obtained through the following steps:
[0080] Addition of CaHA and a functionalizing agent, preferably lactose, dutasteride, urea, or others;
[0081] Dispersion or solubilization of CaHA with added functionalizing agent in an aqueous medium, acidified or not;
[0082] Drying the composition by spray drying.
[0083] In step (A), CaHA and a functionalizing agent are added, preferably lactose, dutasteride, urea, or others. Calcium hydroxyapatite (CaHA) with a hydrodynamic size between 1 and 20 µm is used, preferably 6 µm. 0.1 to 50% of total solids is used, preferably 4%, with 10 to 99.99% (w / w) being CaHA, preferably 90% (w / w), and the remainder being the functionalizing agent.
[0084] In step (B) a dispersion of preferably 4% CaHA with added functionalizing agent is carried out in a variable volume, on a small scale it can be 500 mL of water.
[0085] Optionally, step (B) can be performed in an acidic medium due to the low solubility of CaHA in water. For acidification of the medium, weak organic acids may be used, specifically weak carboxylic acids, including formic acid, acetic acid, propanoic acid, butanoic acid, and benzoic acid, with pKa values between 3 and 5.
[0086] Optionally, in step (C) the composition obtained in (B) is dried by spray drying technique, with a yield of approximately 75%, enabling the industrial scaling up of the present invention.
[0087] In general, the functionalized calcium hydroxyapatite microparticle described in the present invention allows for less aggregation of the microparticles, facilitating incorporation into dermatological formulations such as serums, gels, creams, and others; greater stability of dermatological formulations with less aggregation of microparticles during storage; better interaction with the stratum corneum, through two mechanisms: first, by being less aggregated, and second, by the functionalization providing a less rough surface; a prolonged interaction time with the upper layers of the skin, which can provide desirable complementary cosmetic or pharmacological effects, such as prolonged hydration; and greater targeting to hair follicles, which can provide desirable complementary cosmetic or pharmacological effects, such as targeting molecules that should preferentially act on hair follicles.In addition to reducing particle porosity and surface roughness, decreasing aggregation and simultaneously making it denser, providing ideal ballistic characteristics for delivery via needle-free delivery devices. Thus, the present invention presents an innovative and unprecedented use of calcium hydroxyapatite, which is the passive or active topical use without the use of needles for collagen biostimulation, targeting the upper layers of the skin, such as the epidermis and papillary dermis, enabling aesthetic treatments in sensitive and thin-skinned areas such as around the eyes, concomitant with treatments for skin conditions affecting the aging process, such as dehydration and alopecia, but not limited to them. Examples of embodiments of the invention
[0088] It is known that the use of injectable calcium hydroxyapatite stimulates collagen production. Upon injection of a 25-45 µm calcium hydroxyapatite formulation (Radiesse®) into the dermis, the initial inflammatory process begins through a foreign body reaction. Monocytes are transformed into macrophages and migrate to the site through two processes: absorption of proteins from the surface of the foreign body and macrophage adhesion, and the action of IL-4 and IL-13, produced by TH2 lymphocytes. Fibroblast proliferation then occurs around the injected particles. Fibroblasts secrete growth factors, stimulate the migration of proliferative and inflammatory cells to the region, and mediate the production of collagen and extracellular matrix. Type III collagen is formed around the calcium hydroxyapatite particles, later being replaced by type I collagen.
[0089] It is known that large, high molecular weight, hydrophilic particles have difficulty permeating the stratum corneum, thus making topical application of Radiesse® impossible. Therefore, the only route of administration of CaHA used to date for collagen biostimulation is the injectable route. However, injectable procedures can lead to complications and adverse events such as vascular compromise and nodule formation, which are not related to calcium hydroxyapatite itself, but mainly to application errors.
[0090] The present invention presents itself as a novel and effective alternative for the passive and / or active topical use of calcium hydroxyapatite without the use of needles for the treatment of signs of aging.
[0091] The drying process, preferably using the spray drying technique, allows the functionalizing agent to interact with calcium hydroxyapatite. The functionalization of calcium hydroxyapatite in the present invention allows for less aggregation of microparticles, facilitating incorporation into dermatological formulations such as serums, gels, creams, and others; greater stability of dermatological formulations with less aggregation of microparticles during storage; and better interaction with the stratum corneum. This increased interaction is due to two mechanisms: less aggregation and the functionalization providing a less rough surface, ensuring a prolonged interaction time with the upper layers of the skin.Prolonged interaction with the upper layers of the skin can provide desirable complementary cosmetic or pharmacological effects on signs of aging, such as dehydration, providing prolonged hydration, and alopecia, promoting greater targeting of hair follicles and the action of drugs that should preferentially act on hair follicles, but not limited to these complementary actions.
[0092] The reduced porosity and surface roughness of the particles in the present invention enable the passive topical administration of calcium hydroxyapatite, as well as allowing for less particle aggregation while simultaneously increasing their density. This provides ideal ballistic characteristics for active topical delivery via needle-free delivery devices, proving to be a safer alternative to the injectable use of calcium hydroxyapatite for collagen biostimulation targeting the upper layers of the skin, such as the epidermis and papillary dermis, enabling aesthetic treatments in sensitive and thin-skinned areas such as around the eyes.
[0093] Numerous variations within the scope of protection of this application are permitted. Therefore, it is reinforced that the present invention is not limited to the particular configurations / embodiments described above.
[0094] The examples below are provided to illustrate the best implementation of the invention. It is worth noting that the present invention is not limited to the examples cited and can be used in all the applications described or in any other equivalent variations.
[0095] Example 1: Obtaining microparticles
[0096] The microparticles were produced using the spray drying technique. For this, solutions containing 20 g of solids dispersed in 500 mL of water were used, with 100% corresponding to CaHA for obtaining Micro CaHA or 90% corresponding to CaHA and 10% corresponding to lactose for obtaining functionalized Micro CaHA. A Spray Dryer model MSD 0.5 L (Labmaq, Brazil) was used with the following parameters: atomizing nozzle = 1.0 mm; feed flow = 0.5 L / h; inlet temperature = 110°C. o C, based on the evaporation point of water; compressed air pressure = 5 bar; average air velocity = 0.63 m3 / min; applied volume = 500 mL, to obtain both microparticles.
[0097] The results obtained demonstrated that spray drying is a promising technique for the production and functionalization of CaHA-based formulations. The samples showed satisfactory yields, with values exceeding 74% (CaHA Lac 74.58%, CaHA Urea 74.58%, and CaHA Caffeine 74.73%), indicating that most of the starting material was converted into solid particles.
[0098] The high efficiency of the process, with a yield of approximately 75%, demonstrates that this methodology is suitable for large-scale production, making the invention economically viable and aligned with industry demands.
[0099] Example 2: Morphology of microparticles
[0100] The morphology of the obtained microparticles was analyzed by scanning electron microscopy (SEM). The particles were placed on a support composed of a copper-zinc alloy and coated with gold prior to analysis. The analysis was performed on a JSM-7001F instrument (JEOL, Japan).
[0101] Rounded microparticles with a slightly rough surface can be observed (Figure 1). This morphology allows for prolonged interaction with the upper layers of the skin. Prolonged interaction with the upper layers of the skin may favor complementary treatment of signs of aging, in addition to collagen biostimulation, such as prolonged hydration and increased hair growth.
[0102] Example 3: Zeta potential and PdI of microparticles
[0103] Micro CaHA samples were dispersed in water at a 1:10 ratio. Functionalized Micro CaHA samples were dispersed in ethenal at the same ratio. The zeta potential of all particles was analyzed by determining the electrophoretic mobility of the droplets. The polydispersity index of the microparticles was measured by dynamic light scattering. The analyses were performed using a Zetasizer Nano ZS instrument (Malvern, USA).
[0104] The functionalized microparticles exhibit a polydispersity index of 0.412 ± 0.030 and a zeta potential of -14.6 mV. A negative zeta potential was observed for the functionalized microparticle, as expected and in agreement with the literature for CaHA (CARVALHO et al., 2017; DOS SANTOS, 2013; YOUNG et al., 1997). The closer this value is to 0, the more monodisperse and with less size variation the samples appear (MOGHIMIPOUR, SALIMI, EFTEKHARI, 2013). The median polydispersity index of the functionalized microparticles demonstrates a size variation adequate to the objective of the present invention.
[0105] Example 4: Particle size analysis of microparticles
[0106] The particle size distribution of each of the CaHA-based samples was determined using an LS 13 320 XR laser diffraction analyzer (Beckman Coulter, CA, USA). For the analysis, 100 mg of microparticles were suspended in 10 mL of ultrapure water. The prepared suspensions were analyzed using the Universal Liquid Module (ULM), with ultrapure water used as the dispersing medium.
[0107] The present invention features an average particle size of 6.352 ± 3.201 µm for CaHA Lac Spray (Figure 2), 6.304 ± 3.298 μm for CaHA Urea (Figure 3), and 6.606 ± 3.489 μm for CaHA Caffeine (Figure 4), with at least 20% of the microparticle population being 2 micrometers or larger. The presented particle size allows for topical application of the present invention, in addition to ensuring ideal particle characteristics for ballistic delivery to the skin layers.
[0108] Example 5: Particle size analysis of microparticles during the incorporation process into serum.
[0109] The particle size distribution of each of the CaHA-based samples was determined using an LS 13 320 XR laser diffraction analyzer (Beckman Coulter, CA, USA). For the analysis, 50 mg / g of each microparticle was added to a metabisulfite-based serum and lecigel. The samples were subjected to magnetic stirring. 100 mg aliquots were suspended in 10 mL of ultrapure water for 0.5 minutes, 30 minutes, 60 minutes, and 120 minutes. The prepared suspensions were then analyzed using the Universal Liquid Module (ULM).
[0110] Figure 5 shows that the CaHA functionalization of the present invention (CaHA Lac Spray) facilitates its incorporation into dermatological formulations, since the average size of the particles present in the metabisulfite and lecigel base serum decreases steadily over time. This demonstrates that the functionalization allows for less aggregation of microparticles and better distribution in cosmetic formulations, providing greater stability (Figure 5).
[0111] Example 6: Spreadability analysis
[0112] The spreadability of microparticle samples incorporated into metabisulfite-based serums and lecigels was evaluated using glass plates. For this purpose, a mass of approximately 300 mg was confined between two clean, dry glass plates positioned on millimeter paper. The upper glass plate with a 300 g load was applied for 3 minutes, causing deformation of the sample and allowing quantification of the projected area in mm². This method enables the quantitative comparison of the spreadability of different formulations under controlled conditions, providing relevant data for the development and optimization of cosmetic products.
[0113] The results obtained demonstrate that the spreadability of CaHA-based microparticles (CaHA Spray, CaHA Lac, and the physical mixture CaHA Lac) incorporated into the metabisulfite serum base and lecigel is influenced by both the incorporation time and the type of microparticles used (Figures 6 to 9).
[0114] In general, it was possible to observe the influence of incorporation time, reflecting an increase in spreadability over the course of the study. This fact can be attributed to gradual homogenization in the serum base, with the microparticles dispersing more uniformly in this matrix.
[0115] With the use of functionalized CaHA Lac microparticles, greater spreadability was observed compared to CaHA Spray, especially at longer incorporation times, indicating that the functionalization of CaHA with lactose favors the dispersion of microparticles in the serum base and reduces the formation of aggregates (Figure 7). This fact was confirmed by the reduction in particle size distribution determined by the LS 13 320 XR laser diffraction analyzer (Figure 5).
[0116] Example 7: Analysis of the true density of microparticles (Pycnometer)
[0117] The true densities of CaHA-based microparticles were determined by gas pycnometry using a pycnometer. For this, the powders were gently poured into a cylindrical container (micro measuring cell), and their mass was measured using an analytical balance. Then, the measuring cell was placed in the equipment, and the experiment was performed at 25 °C with pressurization cycles (19 psi) using nitrogen as the reference gas to calculate the displaced volume (v), obtaining the true density (ρ) by the ratio between mass (m) and volume (ρ = m / v). Before measurement, the sample holder was calibrated using two silicon reference spheres. For each sample, the average value was determined from six separate run cycles, which showed a variance of less than 0.1%, ensuring high precision in these measurements.
[0118] The analysis of the true density of the samples showed variations due to the composition and processing method (Figure 10 to Figure 12).
[0119] The CaHASpray microparticle showed the highest density (4.4704 g / cm³). 3 ) due to its compact crystalline structure. Lactose, with a density of 1.5856 g / cm³ 3 , it presented the lowest value due to its organic nature and less dense structure.
[0120] The CaHA Lac formulation showed an intermediate density (3.8574 g / cm³). 3 ), reflecting the functionalization with lactose, which decreased the density compared to CaHA Spray. The physical mixture of CaHA Lac (3.7384 g / cm³) 3 ) showed a slightly lower density, indicating less integration between the phases (inorganic from CaHA and organic from Lac).
[0121] Similar behavior was also observed when the microparticles were functionalized in the presence of urea (Figure 11) and caffeine (Figure 12).
[0122] The results demonstrate that the true density was influenced by the composition and interactions between the materials, directly impacting the final properties of the microparticles. These facts are in agreement with the findings presented in the XRPD analyses, confirming the functionalization of the present invention.
[0123] Example 8: Microparticle compressibility analysis (Hosokawa)
[0124] The compressibility (%) of CaHA-based microparticles was determined using the PT-N equipment (Hosokawa Micron Powder Systems, Summit, NJ, USA). Previously dried samples were analyzed to determine the aerated density (ρa) and the compacted density (ρc). The aerated density was obtained by adding a mass to the standard container without compaction, while the compacted density was measured after applying 180 blows in compaction mode. Compressibility (C) was calculated based on the relative difference between ρa and ρc, using the following equation:
[0125]
[0126] All measurements were performed in triplicate for each sample, and the mean values with relative standard deviation were used in the data analysis.
[0127] The analysis of the aerated density (Figure 13), compacted density (Figure 14), and compressibility (Figure 15) values obtained for the functionalized or non-functionalized CaHA-based microparticles provided complementary information on the behavior of the particles in relation to their packing and compaction efficiency.
[0128] Based on the data obtained, it was possible to better understand the influences of the spray dryer drying process and the addition of functionalizing agents.
[0129] The standard CaHA sample, which was not subjected to the spray dryer drying process, showed the lowest aerated density (0.2432 g / cm³). 3 ) and compacted (0.4865 g / cm 3 ), in addition to the highest compressibility (50.00%). These results suggest that the particles present in this sample have an irregular morphology and pores that can lead to agglomeration.
[0130] For the sample treated only by the spray dryer process (CaHA Spray), there was an increase in both aerated density (0.3378 g / cm³) and aerated density (0.3378 g / cm³). 3 ), as well as in compacted density (0.5405 g / cm 3 ), with a significant reduction in compressibility (37.50%). This result indicates that the atomization process favored the formation of more uniform particles.
[0131] With the presence of the functionalizing agent (lactose), the CaHA Lac microparticles exhibited an aerated density (0.3243 g / cm³). 3 ) and compacted (0.5676 g / cm 3 ) intermediate, with a compressibility value (42.86%).
[0132] Even with the addition of the functionalizing agent (urea), the CaHA Urea microparticles showed the best results in terms of compressibility, with the lowest value among all the samples analyzed (35.14%). Although the aerated density (0.3243 g / cm³) 3) was similar to that of CaHA Lac, the compacted density (0.5000 g / cm 3 The compressibility was lower, suggesting that the addition of urea as a functionalizing agent favored the formation of more cohesive particles. The low compressibility reflects a more compact morphology with less space between particles, demonstrating a positive result of urea on particle behavior.
[0133] Finally, the caffeine-functionalized microparticles showed intermediate values of aerated density (0.2838 g / cm³). 3 ) and compacted (0.5135 g / cm 3 ), but a relatively high compressibility (44.74%).
[0134] The data for aerated density, compacted density, and compressibility showed a significant influence from the application of functionalizing agents and the spray drying process. CaHA Urea stood out, further improving compressibility when compared to CaHA Lac and CaHA Caffeine.
[0135] Example 9: Thermal analysis of microparticles
[0136] Differential scanning calorimetry (DSC) was performed using a DSC-60 instrument (Shimadzu, Japan) at a heating rate of 20 °C / min from 25 to 200 °C, using 3 to 5 mg samples in aluminum pans. A DTG-60H instrument (Shimadzu, Japan) was used for thermogravimetric analysis (TGA) at a heating rate of 10 °C / min from 25 to 500 °C with the same sample quantity as the previous analysis, in platinum pans. All analyses were performed in a nitrogen atmosphere with a flow rate of 50 mL / min.
[0137] DSC analyses of CaHA Lac Spray (Figure 16) and CaHA Urea (Figure 17) show alterations in the melting events when comparing the physical mixtures of CaHA Spray with the functionalizing agents. These events are not observed in the functionalized particles, CaHA Lac Spray and CaHA Urea, but are present, albeit to a lesser extent, in the physical mixtures (Figures 16 and 17). This demonstrates that the functionalizing agent added after spray drying does not functionalize CaHA. On the other hand, the absence of the melting event in both cases confirms the interaction between the elements, proving the functionalization of the present invention.
[0138] TGA analysis shows that CaHA is not degraded under the evaluated conditions, even at high temperatures (500 ºC). Figure 19 shows that lactose undergoes two degradation events. When evaluating the CaHA Lac Physical Mixture, the sum of the events occurring with CaHA and lactose is observed, confirming that there was no interaction between the materials. This data suggests that lactose does not interact with the microparticle when added only after spray drying of CaHA, corroborating the data obtained in the DSC analysis and demonstrating that there is no functionalization of CaHA. In the analysis of CaHA Lac Spray, it is possible to observe the initial water loss and only one lactose degradation event. These analyses confirm the interaction of the active ingredients when they undergo spray drying together, as observed in previous studies (LIMA et al., Powder Technol., 391: 311-320, 2021), confirming, once again, the functionalization of the present invention.
[0139] Figure 20 shows a decrease in degradation events in CaHA Urea when compared to those observed in CaHA Urea Physical Mixture, even though the functionalizing agent is present at the same concentration. This fact, together with the DSC analysis, confirms the interaction and functionalization of the present invention after the drying process under the applied conditions.
[0140] In the DSC analysis of the caffeine-functionalized particle (Figure 18), no melting events are observed in CaHA Caffeine Physical Mixture and CaHA Caffeine. This fact may be related to an adsorption process of the caffeine percentage in the physical mixture, masking the thermal event, which would already be reduced by the fact that it has 10% caffeine in the composition. However, in the TGA analysis (Figure 21), a lower intensity of the caffeine decomposition event with displacement is observed in CaHA Caffeine when compared to CaHA Caffeine Physical Mixture, thus confirming this adsorption and the functionalization of the present invention.
[0141] Example 10: Fourier transform infrared (FTIR) spectroscopy of microparticles
[0142] To characterize the molecular structures and elucidate possible chemical interactions between the components used to produce CaHa-based microparticles, FTIR studies were performed on a Vertex 70v FT-IR spectrometer (Bruker, Madison, WI, USA), using the KBr pellet technique. For pellet production, KBr was previously dried in an oven, and the sample / KBr mixture was applied in a 1:100 (mg / mg) ratio. After homogenization, the mixture was placed in a stainless steel pelleting mold (pelleter), and subsequently, the mold was placed in a hydraulic press and a pressure of 5 tons was applied for 1 minute. The spectra were recorded in transmittance mode, with wavelengths between 4000-400 cm⁻¹. -1 , with 60 scans and a resolution of 2 cm -1 .
[0143] In Figures 22, 23, and 24, FTIR analyses show that calcium hydroxyapatite exhibits the same bands previously observed in the literature, even after drying (CaHA Spray), preserving its chemical characteristics (OFUDJE et al., Sci. Rep., 13(19896): 1-12, 2023). Furthermore, in Figure 22, it is observed that CaHA Lac Spray shows a reduction in band intensities when compared to CaHA Spray and CaHA Lac Physical Mixture. It is possible to observe that the addition of urea (Figure 23) and caffeine (Figure 24) to CaHA Spray modifies the bands present in these isolated active ingredients and decreases the band intensities of CaHA Spray. These facts corroborate the findings presented in the thermal analyses, confirming the functionalization of the present invention.
[0144] Example 11: X-ray powder diffraction (XRPD) of microparticles
[0145] XRPD spectra of individual compounds, CaHA-based microparticles, and physical mixtures were collected using a Bruker D8 Discover X-ray diffractometer (Karlsruhe, Germany). For this analysis, diffraction patterns were obtained at angles in the range of 10° to 60° (2θ) at a scan rate of 0.5° / min-1 and a step size of 0.02°.
[0146] XRPD was applied to characterize the crystalline nature of CaHA and microparticles after the use of functionalizing agents (lactose, urea, and caffeine) through a spray drying process. The results obtained provide information on the crystalline structure and possible alterations in the samples due to functionalization.
[0147] CaHA exhibited diffractometric peaks at 26.04º, 32.06º, 33.05º, 34.29º, 39.97º, 46.89º, and 49.73º. These signals are characteristic of the hexagonal crystalline structure of calcium hydroxyapatite (CaHA). 10(PO4)6(OH)2), demonstrating the presence of a well-defined crystalline phase and confirming the stability and integrity of the original CaHA structure before functionalization (Figure 25) (LONDOÑO-RESTREPO et al., Ceram. Int., 40: 24454-24461,2020; CASTRO et al., Bol. Soc. Esp. Ceram. V., 61(1): 35-41,2022).
[0148] Lactose, used as an agent in functionalization, showed intense and characteristic peaks around 12.6º, 19.2º, 20.1º and 20.8º. These signals serve as a reference to identify the presence of lactose in the functionalized microparticles (Figure 25) (HAQUE, ROOS, Carbohydr. Res., 340(2): 293-301,2005).
[0149] In the XRPD analysis of the functionalized CaHa Lac microparticle (Figure 25), a reduction in peak intensity was observed. This alteration can be attributed to the presence of lactose, which has its own crystalline structure. Furthermore, lactose may contribute to the formation of regions with less crystalline organization in CaHA.
[0150] A reduction in the crystallinity of CaHA was also observed when functionalized with urea or caffeine. Urea, being a highly soluble component, can disperse better in the CaHA matrix during the spray drying process. This can generate a more homogeneous coating, leading to the formation of a partially ordered structure (Figure 26).
[0151] In the case of CaHA caffeine microparticles, although caffeine has a crystalline structure in its pure form (a fact proven by thermal analysis), it can also undergo interactions with CaHA during the spray drying process, resulting in particles with a more disordered structure (Figure 27).
[0152] XRPD results indicate that functionalizing CaHA-based microparticles through spray drying, with the addition of lactose, urea, and caffeine, alters the intensity of crystalline peaks. Reducing the crystallinity of CaHA-based microparticles may be a beneficial alternative in applications requiring more reactive or modified surfaces.
[0153] Example 12: Analysis of the surface area and pore diameter of microparticles
[0154] Nitrogen adsorption-desorption isotherm measurements were performed using a Micromeritics ASAP-2020 porosimeter to determine the surface area, cumulative pore volume, and porosity of the microparticles. To prepare the samples (0.4–0.6 g), they were previously placed under vacuum in the equipment and heated to 100 °C for 720 minutes for degassing. After this preparation, the samples were moved to the analysis compartment, where their surface area and porosity characteristics were measured. The specific surface area was determined using the Brunauer-Emmett-Teller (BET) method, while the Barrett-Joyner-Halenda (BJH) approach was employed to analyze the cumulative pore volume and the average pore size.
[0155] It can be observed in Figure 28 that the functionalization of the present invention results in a decrease in the volume of pores in CaHA Lac Spray when compared to CaHA and CaHA Spray, in which the pores do not undergo volume changes after the spray drying process, as well as a decrease in their surface area observed in Figure 29, in contrast to what is observed in CaHA and CaHA Spray.
[0156] Although previous studies have shown that lactose exhibits an increase in surface area and pore diameter after spray drying with other sugars (EBRAHIMI, SAFFARI, LANGRISH, Powder Technol., 283: 171–177, 2015), suggesting that the interaction between two molecules could generate an increase in surface roughness, the present invention innovates by demonstrating that this material, following a specific process, generates a functionalization that decreases the surface area and pore diameter, resulting in ideal characteristics for active ballistic delivery.
[0157] Example 13: Analysis of the swelling capacity of microparticles
[0158] The study of microparticle swelling was carried out by storing the powders in a humid environment. For this purpose, microparticle formulations (~200 mg) were placed in cylindrical glass containers (internal diameter: 1.9 cm and height: 3.3 cm) and stored in a closed container (desiccator) with controlled temperature and humidity, maintaining an environment of 19 ± 1 °C and relative humidity of 85 ± 5% for up to 1440 minutes. At defined time intervals (10, 30, 60, 120, 240, 360, 480, and 1440 minutes), the samples were removed and mass measurements were performed using an analytical balance to evaluate moisture uptake. The swelling capacity (SC) was obtained from the percentage mass gain of the wet sample and calculated according to the equation below:
[0159]
[0160] Where: Mu is the wet mass, Mf is the final dry mass, and Mi is the initial dry mass of the microparticles. The study was performed in quadruplicate.
[0161] It can be observed in Figures 30 and 31 that CaHA Lac Spray and CaHA Urea exhibit a greater swelling capacity when compared to CaHA Lac Physical Mixture and CaHA Urea Physical Mixture, respectively, and CaHA Spray.
[0162] Although the functionalizing agents in physical mixtures exhibit greater availability for water uptake because they do not interact with CaHA Spray, these particles have a lower swelling capacity compared to the present invention. However, the functionalized microparticles of the present invention are able to capture more water and therefore have the potential to promote hydration for a longer period, an innovative and surprising fact considering the interaction of the compounds and the lower availability of the hydrating agents for water uptake.
[0163] Therefore, physical mixing alone does not guarantee the advantageous and prolonged skin hydration properties that the innovative particle of the present functionalized invention provides.
[0164] Example 14: Incorporation of Calcium Hydroxyapatite into Serum
[0165] In order to obtain a cosmetic formulation for topical use, 50 mg / g of functionalized CaHA Lac (CaHA Lac Spray) was added to a metabisulfite-based serum and lecigel. For complete incorporation of the powder into the vehicle, the sample was subjected to magnetic stirring for a period of 2 hours. This stirring period was selected based on the macroscopic appearance of the formulation and the particle size observed in example 5. The same process was performed for a physical mixture of calcium hydroxyapatite and lactose (CaHA Lac Physical Mixture), i.e., containing all the same components in the same proportions, but without having undergone the drying process that leads to functionalization.
[0166] Example 15: In vitro permeation assay of CaHA Lac Spray
[0167] In vitro permeation assays were performed in vertical diffusion cells with a diffusion area of 1.5 cm². 2 coupled to the Phoenix®DB-6 system (Teledyne Hanson Inc., Chatsworth, CA, USA).
[0168] For passive permeation, cells were mounted using pig ear skin with the stratum corneum facing upwards. The recipient compartment was filled with 15 mL of phosphate buffer solution pH 7.4, and the donor compartment was filled with 1000 µL of the serum obtained in Example 14. 1 g of the formulations obtained in Example 14 was added to the donor compartment. After application of the formulations, the cells were kept at a temperature of 32 ± 1 °C under magnetic stirring at 300 rpm for 24 hours. This assay was performed in triplicate for each sample.
[0169] Following the assay, in order to evaluate the amount of functionalized CaHA Lac permeated, the amount of Ca permeated was quantified by Flame Atomic Absorption Spectrometry (FAAS) using a previously validated analytical method. The same process was performed for CaHA Lac Physical Mixture, i.e., containing all the same components in the same proportions, but without having undergone the process that leads to functionalization.
[0170] It is known that large, high molecular weight, hydrophilic particles have difficulty permeating the stratum corneum (SHAKER et al., Sci. Pharmac., 87(3): 1-34, 2019; SOARES et al., Rev. Ciênc. Farm. Básica e Apl., 36(3): 337-348, 2015), thus making topical application of commercial calcium hydroxyapatite impossible. Therefore, the only route of administration of CaHA used so far for collagen biostimulation purposes is the injectable route.
[0171] Figure 32 shows a passive permeation of approximately 17 µg / cm².2 CaHA Lac Spray and approximately 10 μg / cm³ 2 Physical Mixture of CaHA Lac. Data obtained through in vitro permeation tests demonstrate that the permeation of the present invention is 70% greater than that of the physical mixture, corroborating that the functionalization of CaHA provides more effective permeation through the stratum corneum due to its better interaction with this layer, and that the physical mixture of the active ingredients present in this invention is not sufficient.
[0172] Therefore, topical administration of CaHA becomes feasible and more effective with the use of the present invention in topical cosmetic formulations, proving to be a safer alternative to injectable CaHA for the treatment of signs of aging, especially in areas of thin skin where injection is not a viable option.
[0173] Example 16: Incorporation of Dutasteride into Serum
[0174] In order to obtain a cosmetic formulation for topical use, 0.25 mg / mL of CaHA Duta Spray was added to gluncam serum. For complete incorporation of the powder into the vehicle, the sample was subjected to magnetic stirring for a period of 10 minutes. The same process was performed for a physical mixture containing free Dutasteride, that is, containing all the same components in the same proportions, but without having undergone the drying process that leads to functionalization. The two formulations obtained were then used in a permeation experiment in order to verify the targeting to the hair follicle.
[0175] Example 17: Targeting CaHA Duta Spray to the hair follicle
[0176] In vitro permeation studies were performed in vertical diffusion cells with a diffusion area of 1.5 cm². 2 coupled to the Phoenix®DB-6 system (Teledyne Hanson Inc., Chatsworth, CA, USA).
[0177] For passive permeation, cells were mounted using pig ear skin with the stratum corneum facing upwards. The recipient compartment was filled with 15 mL of phosphate buffer solution pH 7.4, and the donor compartment was filled with 1000 µL of the serums obtained in example 16. After application of the formulations, the cells were maintained at a temperature of 32 ± 1 °C, under magnetic stirring at 300 rpm for a period of 12 hours. This assay was performed in sextuplicate for each sample.
[0178] Following the assay, the skin layers were separated using the differential tape striping technique. After separation, the skin layers (stratum corneum, remaining skin, and hair follicle) were placed in small vials and subjected to an extraction process using 2.5 mL of methanol for 24 hours with agitation. Finally, the amount of Dutasteridated in each skin layer was quantified by High-Performance Liquid Chromatography (HPLC) using a previously validated analytical method.
[0179] The results presented in Figure 33 demonstrate that free Dutasteride (Duta) is more present in the remaining skin than Dutasteride present in functionalized CaHA microparticles (CaHA Duta Spray). Furthermore, it can be observed in Figure 34 that CaHA Duta Spray shows a 2.9 times greater targeting of Dutasteride to the hair follicle when compared to that observed with free Dutasteride.
[0180] The topical use of CaHA Duta Spray becomes interesting since dutasteride acts by inhibiting the action of type I and type II 5α-reductase, promoting an effective treatment for hair disorders, such as androgenetic alopecia, at lower doses than finasteride. However, a large amount of drug permeated into the remaining skin can increase its systemic side effects due to the vascularization of the dermis, such as decreased libido, ejaculation disorders, gynecomastia, dizziness, headache, and fatigue (AFIUNE et al., Int. J. Pharm., 587: 1-10, 2020; FANG et al., Ther. Deliv., 5(9): 991-1006, 2014).
[0181] The present invention is advantageous compared to the use of free dutasteride because it results in lower amounts of drug permeated into the remaining skin, as well as greater targeting to the hair follicle, increasing the effectiveness of the treatment by acting directly on the site of action of 5α-reductase inhibitors, even with the use of lower doses, and reducing the systemic side effects of the drug.
[0182] Example 18: Evaluation of tissue viability using the MTT assay.
[0183] Cell viability was assessed using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) reduction colorimetric assay, which is based on the ability of viable cells to reduce the tetrazolium salt into formazan crystals. For the experiment, 7,000 human fibroblasts (biological triplicate), 250,000 PBMCs (technical triplicate), and 25,000 HaCat (technical triplicate) were plated in 96-well plates. After 24 hours of incubation, cell adhesion was confirmed, and the medium was replaced with fresh culture medium containing microCaHA at different concentrations. After 48 hours of incubation, the medium was again replaced with 90 µL of fresh medium supplemented with 10 µL of MTT solution (5 mg / mL in PBS). The plates were incubated for 4 hours at 37°C in a 5% CO2 atmosphere, protected from light. Then, the MTT-containing medium was removed and 100 µL of dimethyl sulfoxide (DMSO) was added to solubilize the formazan crystals.For MTT analysis, readings were taken at wavelengths of 650 and 570 nm. The baseline value (650 nm) was subtracted from all groups, and then the blank was also subtracted. The positive control (DMEM) was considered to represent 100% viability, and the remaining groups were normalized based on it.
[0184] Different concentrations, ranging from 0.002% to 0.25%, were evaluated over a 48-hour period in different cell types. In the viability assay, 7 × 10 cells were initially seeded. 4 fibroblasts, 250,000 PBMCs, and 25,000 HaCat cells. None of the treatments reduced cell viability by 50% or more in any of the models tested.
[0185] After 48 hours of treatment, a significant decrease in cell viability was observed at concentrations of 0.125% and 0.25% for fibroblasts. In PBMCs, this reduction was evident from 0.0313%. These results corroborate literature data reporting the absence of significant cytotoxicity of CaHa in human fibroblasts at concentrations as low as 0.1%.
[0186] In fibroblasts, a significant reduction in cell viability was observed at concentrations of 0.0078%, 0.0156%, and 0.0313%; however, the concentration of 0.0625% did not result in a significant decrease (Figure 35A). For PBMCs, viability was significantly reduced only at a concentration of 0.125% (Figure 35B). In HaCat, a much greater reduction in viability was observed starting at 0.125% (Figure 35C).
[0187] Based on these findings, the concentrations selected for subsequent collagen production assays were 0.0625% for experiments conducted exclusively with fibroblasts or fibroblasts cultured with HaCat supernatants. For experiments involving PBMCs, a concentration of 0.0313% was chosen.
[0188] Example 19: Cumulative toxicity assessment over 4 weeks using the MTT assay.
[0189] To investigate the potential toxicity of microCaHA treatment over time, a cell viability assay using MTT was performed over a period of 4 weeks. The maximum non-toxic concentration, previously determined in the first cell viability assay (0.0625%), was used. Fibroblasts were exposed to the treatment for 48 hours each week. In the first week, cells received a single treatment exposure before the MTT assay. In the second week, cells underwent two treatment exposures, and this pattern was maintained for subsequent weeks, with the number of treatments progressively accumulating until the fourth week.
[0190] To investigate the potential cumulative toxicity of micro CaHA over 28 days, a cell viability experiment was conducted. Initially, fibroblasts were seeded at densities of 2 × 10³, 2 × 10⁵, and 7 × 10³ cells / well and treated with a fixed concentration of 0.0625%. The experimental protocol consisted of weekly treatment application, with the number of doses progressively accumulating: the first group received one dose at the end of the first week, the second group two doses at the end of the second week, and so on, until the fourth week.
[0191] The results indicated that the treatment did not cause a significant reduction in cell viability when fibroblasts were initially seeded at a density of 2 × 10³ cells / well (Figure 36A). For higher cell densities, an initial reduction was observed followed by an increase in viability over time (Figure 36B-C). This behavior can be attributed to the high cell density, which promotes a high proliferation rate, resulting in the detachment of some cells and, consequently, the release of space for new cell divisions. These data reinforce that microCaHA does not exhibit cumulative cytotoxicity in fibroblasts, even after multiple weekly exposures.
[0192] Example 20: Tissue viability assessment
[0193] Tissue viability was assessed using the 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) colorimetric metabolism method, used as an indicator of the tissue's metabolic state, distinguishing metabolically active from inactive regions. Skin fragments were cultured in an ex vivo human skin model. Briefly, the skin was disinfected, the hypodermis removed and sectioned into 6 mm discs using punches. These fragments were positioned on a sterile metal grid in 6-well plates, with the dermis in contact with the culture medium (DMEM supplemented with 10% FBS and 1% penicillin / streptomycin) and the epidermis exposed to air. Incubation occurred at 37°C and 5% CO2. The skin fragments were then topically treated with a serum containing micro CaHA for 48 hours and 7 days.
[0194] The group treated with 20% SDS was included as a negative viability control. After the incubation period, skin fragments were transferred to 24-well plates, one fragment per well. Then, 1 mL of 2% TTC solution, diluted in DMEM without phenol red, was added to each well, and the plates were incubated for another 2 hours. After incubation, the fragments were washed with PBS and subsequently with a mixture of 70% ethanol and DMSO (1:1, v / v). Extraction was performed at room temperature overnight in a shaker protected from light. Samples of 200 µL from each well were transferred to 96-well plates, where absorbance was measured at 485 nm for tissue viability quantification.
[0195] After 48 days of treatment, it was observed that there was no reduction in tissue viability below 50%, with the CaHA Lac treatment showing the greatest reduction in tissue viability (Figure 37A). After 7 days of treatment, it was observed that both standard CaHA and functionalized CaHA maintained good tissue viability, with CaHA Spray being the group that showed the lowest viability after 7 days (Figure 37B). It should be noted that no statistical tests were applied because the experiment was conducted with only one replicate.
[0196] Example 21: Test for evaluating calcium deposits
[0197] To evaluate the internalization of microCaHA by cells, the presence of calcium deposits was analyzed using Alizarin Red staining. For the experiment, 70,000 fibroblasts were seeded in 6-well plates and cultured until adhesion. After this period, the cells were treated with microCaHA at a concentration of 0.0625% for 48 hours. At the end of this treatment, some cells were stained with Alizarin Red, while another group was kept in culture for 7 days (2 days of treatment followed by 5 days of culture without microCaHA) before staining. This protocol allowed the evaluation of calcium deposition at different exposure times to microCaHA.
[0198] The results obtained through alizarin red staining indicate the presence of calcium deposits, evidenced by the reddish coloration in the fibroblasts. A progressive intensification of the staining can be observed over time, being more evident after 7 days of treatment (Figure 38B), suggesting an increase in mineralization with the progression of the culture time, which may indicate the effectiveness of the treatment in promoting calcium deposition over time.
[0199] Example 22: Collagen quantification
[0200] For this assay, 70,000 fibroblasts were co-cultured with 2.5 million PBMCs treated with 0.0313% of each treatment (CaHA Lac physical mixture, Functionalized CaHA, and CaHA Spray). In addition to co-culture, fibroblasts were also cultured with the supernatant of 2.5 million PBMCs previously cultured for 48 hours of treatment with the different treatments at 0.0313% in DMEM, supplemented with 10% FBS and 1% penicillin / streptomycin, at 37°C, 5% CO2, and 95% humidity.
[0201] After the treatment period, the supernatant was collected and reserved. The cells were washed with PBS, scraped with a cell scraper, and suspended in PBS. Samples, both from the supernatant and the scraped cells, were sonicated three times for 15 seconds, with 30-second intervals, at 50% amplitude, while being kept on ice.
[0202] Next, 9 mL of 25% ammonium sulfate solution were added to the sonicated samples, and the mixture was stirred for 24 hours at 4°C. The samples were centrifuged at 40,000 × g for 40 minutes at 4°C, and the supernatants were discarded. The resulting pellets were solubilized in 2 mL of 0.5 M acetic acid. Then, 0.8 mL of Sirius Red solution (100 µg / mL) was added to 200 µL of the samples, with vortex stirring. After resting for 30 minutes at room temperature, the samples were centrifuged at 30,000 × g for 40 minutes at 4°C, and the supernatant was discarded. The pellets were eluted in 1 mL of 0.1 M KOH, and 100 µL of each sample was transferred to 96-well plates.
[0203] A standard curve for type I collagen was generated from serial dilutions of the collagen standard (Sigma) in Sirius Red. Absorbance was measured at 540 nm using a microplate reader.
[0204] After analyzing the quantification of collagen in fibroblasts treated with micro CaHA at a concentration of 0.0313%, with or without the influence of peripheral blood mononuclear cells (PBMCs), an increase in extracellular collagen production was observed. Although this increase was not statistically significant, treatment with functionalized CaHA alone resulted in a 147.7% increase compared to the untreated control (Figure 39A). In fibroblasts treated with functionalized CaHA and stimulated with previously treated PBMCs for 48 hours, the increase was 134.6%. When maintained in co-culture with PBMCs, collagen production increased by 135.4%, while the system containing the physical mixture of the components demonstrated a 136.2% increase compared to the control (Figure 39B-C).
[0205] Regarding intracellular collagen, all treatments promoted an increase in quantification, except in the co-culture system, where the control showed the highest values (Figure 39C). In the treatment with only Functionalized CaHA, a 133.3% increase in collagen quantification was observed compared to the other groups in this culture system. In the stimulation with PBMC supernatant, CaHA Spray resulted in a 153.5% increase, while Functionalized CaHA showed an 85.3% increase. In the co-culture system, the physical mixture promoted a 118.2% increase, and Functionalized CaHA, 93.3%.
[0206] Although no statistically significant difference was detected between the treatments with functionalized CaHA and the control, it is noteworthy that CaHA Lac demonstrated a greater capacity to stimulate collagen production, especially when considering both intracellular and extracellular collagen (Figure 39).
[0207] To observe the interaction between keratinocytes and fibroblasts in collagen production, 250,000 HaCat cells were pre-treated with 0.0625% micro CaHA for 48 hours. After this period, the supernatants from these cells were collected and used to treat 70,000 fibroblasts for collagen quantification (Figure 40). It should be noted that no statistical tests were applied because the experiment was performed with only one replicate.
[0208] Example 23: Staining collagen fibers with Sirius Red
[0209] Sirius Red staining was performed on monolayers of previously treated fibroblasts. The cells were fixed with 4% formaldehyde for 10-15 minutes, followed by washing with PBS and permeabilization with 0.1% Triton X-100 for 5 minutes. Subsequently, the Sirius Red solution (1 mM) was applied, with incubation for 60 minutes at room temperature. After staining, the samples were sequentially washed with PBS and 70% ethanol to remove excess dye. Collagen fibers were analyzed using an optical microscope; however, differentiation between fiber types was limited by the absence of a polarized light microscope, equipment necessary for more precise visualization, especially of type I fibers.
[0210] For visualization and qualitative analysis of collagen fibers after treatment, monolayers of fibroblasts previously exposed to 0.0625% microCaHA were stained with Sirius Red, as described in the methodology. Collagen fibers were analyzed using an optical microscope. However, precise differentiation between fiber types, especially type III, was limited by the absence of a polarized light microscope, essential for this distinction. A more intense red staining was observed in cultures treated with functionalized microCaHA, suggesting an increase in collagen synthesis or organization in response to treatment both after 48 hours of treatment and after 7 days (Figure 41).
[0211] After photodocumentation, in order to perform quantitative analysis of collagen fibers, 1 mL of 0.1 M KOH was added to solubilize the Sirius Red bound to the collagen fibers, and after incubation for 15 minutes, the solution was transferred to a 96-well plate and the absorbance was read at 540 nm.
Claims
CALCIUM PHOSPHATE SALTS MICROPARTICLES, characterized by having a size measured by microparticle light diffraction technique, with at least 20% of the population having a diameter greater than 2 micrometers, and by being functionalized with an agent that provides at least one of the following properties: Reduced aggregation of microparticles, facilitating incorporation into dermatological formulations such as serums, gels, creams, and others; Greater stability of dermatological formulations with less aggregation of microparticles during storage; Better interaction with the stratum corneum, through two mechanisms: first, by being less aggregated, and second, by the functionalization providing a less rough surface; Prolonged interaction time with the upper layers of the skin, which can provide desirable complementary cosmetic or pharmacological effects, such as prolonged hydration;Greater targeting of hair follicles, which can provide desirable complementary cosmetic or pharmacological effects, such as targeting molecules that should preferentially act on hair follicles; Increase its potential to induce collagen production; Provide an anti-sagging effect in cases of aging or significant weight loss; Decrease particle porosity and surface roughness, reducing aggregation and at the same time giving these microparticles ideal ballistic characteristics for delivery via needle-free delivery devices. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application in pharmaceutical formulations, including topical pharmaceutical formulations and cosmetic formulations. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application in pharmaceutical or cosmetic formulations for the purposes of collagen biostimulation and rejuvenation. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application in pharmaceutical or cosmetic formulations for the purpose of preventing skin sagging in cases of aging or significant weight loss. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application using pressure devices without the use of needles, for the purpose of collagen biostimulation and rejuvenation. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application using pressure devices without the use of needles, for the purpose of preventing skin laxity in cases of aging or significant weight loss. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application using microneedle injection devices, for the purpose of collagen biostimulation and rejuvenation. USE OF CALCIUM PHOSPHATE SALTS MICROPARTICLES FUNCTIONALIZED WITH MOLECULES THAT PROVIDE AT LEAST ONE OF THE PROPERTIES DESCRIBED IN CLAIM 1, characterized by comprising application using microneedle injection devices, for the purpose of preventing skin laxity in cases of aging or significant weight loss.
